Part 1 of 5 in Circle's Coronary Plaque series.

Consider a familiar scenario. A 52-year-old presents with atypical chest discomfort. The stress test is borderline. The referring physician is uncertain — is this true coronary disease, or something else? Standard imaging has been done. The anatomy looks, on the surface, mostly normal. And yet something about this patient doesn't sit right.

This is the case where clinicians have historically had to make consequential decisions with incomplete information. Escalate to invasive angiography and risk an unnecessary procedure. De-escalate and risk missing a vulnerable plaque that hasn't yet caused significant stenosis — but will.

Coronary artery disease doesn't announce itself neatly. A substantial share of acute coronary events occur in patients with non-obstructive coronary disease — lesions that would not have triggered revascularization on a standard angiogram. The stenosis grade has always been an imperfect surrogate for risk. What matters is the plaque itself: its composition, its burden, and its vulnerability.

Advanced CCTA plaque analysis changes that calculus.

Beyond Stenosis: What Plaque Characterization Actually Tells You

Coronary CT angiography is already the most guideline-supported non-invasive modality for evaluating stable chest pain. The 2021 ACC/AHA Chest Pain Guidelines elevated CCTA to a Class I recommendation for initial evaluation — a reflection of trial data from SCOT-HEART and PROMISE showing superior diagnostic accuracy and meaningfully better downstream outcomes.

But standard CCTA reporting stops at stenosis. The next frontier is what the plaque looks like — and that requires dedicated post-processing analysis.

High-risk plaque features identified on CCTA carry independent prognostic weight:

• Low-attenuation plaque (LAP): Lipid-rich necrotic core content associated with plaque vulnerability
• Positive remodeling: Outward arterial expansion that masks stenosis severity while indicating active plaque development
• Spotty calcification: Small, isolated calcium deposits correlated with plaque instability
• Pericoronary adipose tissue (PCAT): A marker of coronary inflammation detectable on standard CCTA datasets

The PARADIGM registry, one of the largest longitudinal CCTA studies, demonstrated that whole-heart plaque burden and progression — not just stenosis — independently predict major adverse cardiovascular events. More recently, 10-year outcomes from SCOT-HEART showed a sustained reduction in coronary heart disease death and non-fatal MI in patients managed with CCTA-guided care, and the ongoing SCOT-HEART 2 trial is now testing CCTA as a primary-prevention screening tool against standard risk scoring.

This is not an emerging research concept. It is becoming a clinical standard — and the gap between sites that can do it and sites that can't is widening.

The Diagnostic Confidence Problem

The challenge for most programs isn't awareness. Cardiologists and radiologists increasingly understand what plaque analysis offers. The challenge is access: most CCTA reporting workflows were built for stenosis assessment and were never designed to support quantitative plaque characterization.

Manual plaque analysis is time-consuming and prone to inter-observer variability. Dedicated standalone tools require separate logins, separate data pipelines, and a workflow that doesn't integrate cleanly with the reading environment clinicians already use. The result is that plaque characterization gets done inconsistently — on selected cases, by certain readers, when time permits.

That inconsistency has consequences. It means the same patient might receive a comprehensive plaque report at one visit and a stenosis-only report at the next. It means risk stratification quality varies by reader and by shift. And it means that the borderline case — the 52-year-old with atypical symptoms and a mostly normal scan — may not get the full picture needed to make a confident call.

What Changes When Plaque Analysis Is Built Into the Workflow

cvi42 integrates CCTA plaque analysis natively within the same post-processing environment used for cardiac MRI, CT function, and structural heart assessment. The result is a materially different clinical experience.

Quantitative plaque metrics — total plaque volume, LAP volume, percent atheroma volume, high-risk plaque feature scoring — are generated within the same workspace where the clinician reviews anatomy, function, and prior studies. There is no separate login, no data export, no switching between applications. The plaque data is part of the report, not appended to it afterward.

For the borderline case, that integration matters. A cardiologist reviewing a CCTA can see, in a single view, that a lesion with 40% stenosis also carries high LAP burden — changing the risk interpretation and supporting a more aggressive preventive management decision. Or the reverse: a case that looks alarming on anatomy shows low-burden, calcified, stable plaque — supporting confident de-escalation and a clear patient conversation.

This is the kind of nuanced, evidence-based characterization that current ACC/AHA prevention guidelines call for. cvi42 makes it achievable in standard clinical workflow, not just in research centers.

From Uncertainty to a Defensible Decision

There is also a medicolegal dimension to this conversation that cardiologists and radiologists are increasingly aware of. Missed plaque diagnoses — particularly in patients who subsequently present with acute coronary syndrome — are among the most scrutinized claims in cardiovascular imaging litigation. A reporting workflow that produces only stenosis data, when AI-assisted plaque characterization was available and guideline-supported, is increasingly difficult to defend.

The standard of care is moving. Adopting a platform that supports guideline-concordant plaque analysis is not just a clinical choice — it is a professional risk management decision.

Putting It Together

Advanced coronary plaque analysis represents one of the most significant advances in non-invasive cardiovascular imaging in the past decade. The clinical evidence is mature. The guidelines are aligned. The technology to do it efficiently, in standard workflow, now exists.

The 52-year-old with the borderline stress test and the atypical symptoms deserves more than a stenosis grade. With cvi42, you have the plaque insights to tell the full story — and the confidence to act on it.

Book a cvi42 demo to see coronary plaque analysis  →

Stay tuned for more on Advanced Plaque Analysis from the perspective of IT and PACS administrators, CFOs and finance leadership, imaging lab directors and department heads.